Personalised Melanoma Vaccine Cuts Recurrence Risk by 42% in Clinical Trial

An experimental vaccine tailored to individual patients has shown promising results against melanoma, with a reported 42% reduction in the risk of the skin cancer returning.

The findings came from a Phase III clinical trial assessing the personalised treatment. The vaccine is designed for each patient rather than offered as a single, uniform formulation.

The approach aims to help treat people who have already developed melanoma by reducing the likelihood of recurrence, rather than serving as a routine vaccine to prevent skin cancer.

The reported results point to potential progress in personalised cancer treatment. However, the available summary did not provide details on the trial’s size, comparison treatment, follow-up period or safety findings, leaving important questions about the results unanswered.